Dapagliflozin, a type 2 diabetes medication, has shown potential benefits post myocardial infarction

Dapagliflozin, a type 2 diabetes medication, has shown potential benefits post myocardial infarction (MI) in some studies. It may help reduce the risk of cardiovascular events and heart failure in patients with diabetes and a history of MI. Additionally, dapagliflozin has demonstrated improvements in renal outcomes. However, it's crucial to note that individual responses to medications can vary, and consultation with a healthcare professional is essential to determine the most appropriate treatment based on an individual's specific medical history and condition.